C

ChemoCentryx Inc
F:2CX

Watchlist Manager
ChemoCentryx Inc
F:2CX
Watchlist
Price: 51.89 EUR
Market Cap: €3.7B

Gross Margin

57.5%
Current
No historical data
Comparison unavailable

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
57.5%
=
Gross Profit
$18.2m
/
Revenue
$37.3m

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
57.5%
=
Gross Profit
€18.2m
/
Revenue
$37.3m

Peer Comparison

Country Company Market Cap Gross
Margin
US
ChemoCentryx Inc
F:2CX
3.7B EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
67th
Based on 12 729 companies
67th percentile
57.5%
Low
-24 813% — 28.9%
Typical Range
28.9% — 60.5%
High
60.5% — 10 905 714.3%
Distribution Statistics
the United States of America
Min -24 813%
30th Percentile 28.9%
Median 43%
70th Percentile 60.5%
Max 10 905 714.3%

ChemoCentryx Inc
Glance View

Market Cap
3.7B EUR
Industry
Biotechnology

Nestled in the bustling hub of biopharmaceutical innovation, ChemoCentryx Inc. has carved out a unique niche in the world of healthcare, focusing on the development of orally administered therapeutics to combat autoimmune diseases, inflammatory disorders, and cancer. Founded in 1996, this biotechnology pioneer operates with a deep-seated commitment to harnessing the science of chemokine receptors and their associated pathways. ChemoCentryx's core strategy revolves around precision medicine, aimed at modulating the immune system to treat vexing diseases while minimizing traditional treatment pitfalls. By targeting specific pathways involved in the body's inflammatory response, the company endeavors to offer therapies that not only alleviate symptoms but potentially alter the course of diseases. Central to ChemoCentryx's business model is its flagship product, TAVNEOS® (avacopan), approved in several markets for the management of ANCA-associated vasculitis, a rare and potentially life-threatening disease. This product exemplifies their approach: focusing on challenging therapeutic areas with significant unmet medical needs. Revenue streams are predominantly generated through the commercialization of such novel drugs, supplemented by strategic partnerships with major pharmaceutical companies. These alliances not only enhance their research capabilities but also broaden their potential market reach. By combining cutting-edge science with strategic business acumen, ChemoCentryx stands at the frontier of fostering innovative solutions to some of the most daunting health challenges.

2CX Intrinsic Value
Not Available
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
57.5%
=
Gross Profit
$18.2m
/
Revenue
$37.3m
How has Gross Margin changed over time?

Over the last 6 months, ChemoCentryx Inc’s Gross Margin has increased from 7.1% to 57.5%. During this period, it reached a low of 7.1% on Dec 31, 2021 and a high of 51.3% on Jul 30, 2022.

Back to Top